MANNHEIM, Germany (AP) — MANNHEIM, Germany (AP) — Affimed N.V. (AFMD) on Thursday reported a loss of $16.6 million in its third quarter.
On a per-share basis, the Mannheim, Germany-based company said it had a loss of $1.03.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.14 per share.
The drug developer posted revenue of $170,400 in the period. Its adjusted revenue was $170,000.
The company's shares closed at $3.75. A year ago, they were trading at $3.28.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AFMD at https://www.zacks.com/ap/AFMD
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.